WuXi XDC Cayman Inc.

Leading global CRDMO focused on antibody-drug conjugates (ADCs) and bioconjugates. Provides integrated end-to-end discovery, development and manufacturing services. Joint venture of WuXi Biologics and WuXi STA, spun off and listed on HKEX (2268.HK) in 2023. Facilities in China and Singapore.

To provide comprehensive coverage, we aggregate data and news under the name WuXi XDC, encompassing the following company names, divisions, and related entities:

藥明合聯生物技術有限公司.

This list encompasses current and former names, alternate names, and key divisions associated with WuXi XDC, ensuring you can easily find all relevant information under a single, unified profile.